Cephalon, Inc. NASDAQ: CEPH increased 1.44% to close at $62.68 CEPH traded 1.38 million shares for the day. Its earning per share remained $5.00. Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and commercialization of products in four core therapeutic areas: central nervous system (NYSE:CNS), pain, oncology and inflammatory disease. In addition to conducting an active research and development program, it markets seven products in the United States and numerous products in various countries throughout Europe and the world. Its principal product are its wakefulness products, PROVIGIL (modafinil) Tablets [C-IV] and NUVIGIL (armodafinil) Tablets [C-IV], which comprised 51% of its total consolidated net sales during the year ended December 31, 2009. During 2009, Cephalon, Inc. acquired an exclusive, worldwide license to the ImmuPharma investigational compound, LUPUZOR, which is in Phase IIb development for the treatment of systemic lupus erythematosus.
DENTSPLY International Inc. NASDAQ: XRAY decreased 0.22% to close at $31.79 XRAY traded 1.06 million shares for the day. Its earning per share remained $1.85. DENTSPLY International Inc (DENTSPLY) is a designer, developer, manufacturer and marketer of a range of products for the dental market. The Company conducts its business through four operating segments, all of which are primarily engaged in the design, manufacture and distribution of dental products in three principal categories: dental consumables, dental laboratory products and dental specialty products. The Company conducts its business in over 120 foreign countries, principally through its foreign subsidiaries. DENTSPLY has a presence in Canada and in the European market, particularly in Germany, Switzerland, France, Italy and the United Kingdom. It also has a market presence in Central and South America, including Brazil, South Africa and Pacific Rim.
Endo Pharmaceuticals NASDAQ: ENDP increased 1.92% to close at $34.99 ENDP traded 2.66 million shares for the day. Its earning per share remained $2.63. Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company in pain management. The Company is engaged in the research, development, manufacturing, marketing and sales of branded and generic pharmaceutical products used primarily to treat and manage pain, overactive bladder, prostate and bladder cancer and central precocious puberty. Its portfolio of branded products includes Lidoderm, Opana ER and Opana, Percocet, Frova, Voltaren Gel, Vantas, Valstar and Supprelin LA. The Company concentrates on generics that have one or more barriers to market entry, such as complex formulation, regulatory or legal challenges or difficulty in raw material sourcing.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.
Disclosure: No positions